The $5.4 billion acquisition of Global Blood Therapeutics by Pfizer was sealed with a phone call and a commitment to reach patients with sickle cell disease wherever in the world they live.
Teva Pharmaceuticals is taking a long-running battle over generic drug labeling to the U.S. Supreme Court.
2022 STAT Summit to feature Pfizer Chairman & CEO, Albert Bourla, Merck Executive Chairman, Ken Frazier, and Eli Lilly Chair & CEO, Dave Ricks BOSTON, MA – Today, STAT, the nation’s must-read health, science, and medicine publication, is proud to announce the 2022 STAT Summit. The two-day, in-person event will take place on November 15-16,…
Nov 15 & 16Boston#STATSummit Register nowView Speakers About From trials to triumph: healing medicine's ailments A multi-year pandemic has brought no end of trials, but also plenty of triumphs. Come for a silo-breaking and solution-focused discussion of the most important topics in health care with some of the industry's greatest minds. Join the program virtually,…
Pfizer said a much-watched study of its antiviral Paxlovid in patients who have Covid but don’t have risk factors for severe disease failed to show a benefit in speeding alleviation of Covid symptoms, but did seem to prevent doctor’s visits and hospitalizations.
“At some point, there will be Paxlovid-resistant virus," said Adam Lauring, who studies RNA virus evolution at the University of Michigan. "Whether that clinically becomes a problem or not, it’s hard to say.”
In an ambitious move to widen access to its medical products, Pfizer said it plans to provide nearly two dozen patent-protected medicines and vaccines at not-for-profit prices to 45 poor countries.
Early on, clinicians ruled out the most concerning possibility for Paxlovid rebound: that the virus was evolving resistance to the drug, a prospect that could undermine the treatment before it even had time to take off.
With three doses, the vaccine was well tolerated, induced a strong immune response, and was 80.3% effective at preventing Covid infections
The NIH has agreed to license nearly a dozen technologies to a WHO program created to boost access to Covid-19 treatments, vaccines, and diagnostics.
All told, Sen. John Thune raked in more than $35,000 from pharmaceutical companies in February.
The end of a national right to abortion could trigger a surge of interest in abortion pills by mail, a method that has become popular in states that already restrict the procedure.
Biogen, a stalwart of the global drug industry for the past four decades, is perilously poised for 2022, with its best hope for growth another risky Alzheimer's therapy.
The story of Paxlovid is a reminder that the path from a biological idea to a useable medicine depends on thousands of decisions, any of which can result in the medicine not making it.
“Using the claim of a human rights violation to prevent equitable access to its Covid medicines is neither ethical nor responsible."
What is now happening recapitulates some of the events of last summer and fall, when company executives drove the narrative that a third mRNA vaccine dose was essential for all Americans.
“It’s better than nothing, but it’s worryingly small numbers and hardly calls for a salutary reaction toward Pfizer,” said Peter Maybarduk of Public Citizen.
As the war in Ukraine has prompted an exodus of international companies from Russia, drug companies said they would continue manufacturing and selling their products there.
Disputes over the White House’s lack of transparency are imperling its efforts to get more Covid-19 money — and the budget crunch is more severe than the administration has let on.
“Of all the companies in which we invested, Pfizer was both the least transparent and least collaborative,” a former Operation Warp Speed official writes in a new book.
The Greek-born Bourla took the reins as Pfizer’s CEO in January 2019, and barely had time to get settled in when the pandemic hit. Yet he has stepped up to meet the crisis like few others. Pfizer became the first drug maker to gain U.S. approval of an mRNA vaccine against Covid-19 in late 2020,…
Pfizer, the company behind a Covid vaccine and a Covid pill, has named a new top development executive as Covid remakes the company.
Biogen is selling its stake in a biosimilars joint venture for $2.3 billion, adding to the company's cash reserves as investors clamor for M&A.
Pfizer and BioNTech have started a trial evaluating an adapted version of their Covid-19 vaccine targeting the Omicron variant of the coronavirus.
An advocacy group is pressing Pfizer to swiftly expand access to it pill to treat Covid-19 in low-income countries.
A rundown of what to look for at this year's J.P. Morgan Healthcare Conference.
The Food and Drug Administration on Wednesday authorized Paxlovid, a pill developed and made by Pfizer, as a treatment for Covid-19, a significant step in the battle against the SARS-CoV-2 virus.
At best, claims of widespread vaccine hesitancy across African nations are uninformed speculation. At worst, they are attempts to distract people from the injustice of unequal access to Covid-19 vaccines by blaming Africans.
[email protected] names his best biopharma CEO of 2021, plus some runners-up.
